We are live on ! Find out more
RGNX icon

Regenxbio

171 hedge funds and large institutions have $717M invested in Regenxbio in 2023 Q4 according to their latest regulatory filings, with 32 funds opening new positions, 47 increasing their positions, 61 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

60% more first-time investments, than exits

New positions opened: 32 | Existing positions closed: 20

50% more funds holding in top 10

Funds holding in top 10: 23 (+1)

18% more capital invested

Capital invested by funds: $610M → $717M (+$107M)

8% more funds holding

Funds holding: 159171 (+12)

6.54% more ownership

Funds ownership: 84.26%90.8% (+6.5%)

14% less call options, than puts

Call options by funds: $1.74M | Put options by funds: $2.02M

23% less repeat investments, than reductions

Existing positions increased: 47 | Existing positions reduced: 61

Holders
171
Holders Change
+12
Holders Change %
+7.55%
% of All Funds
2.49%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.04%
New
32
Increased
47
Reduced
61
Closed
20
Calls
$1.74M
Puts
$2.02M
Net Calls
-$279K
Net Calls Change
-$2.69M

RGNX Hedge Fund Activity: Q4 2023 in Review

171 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Regenxbio (RGNX) for Q4 2023, worth a combined $717M — up 18% from $610M a quarter earlier.

Buyers outnumbered sellers: 32 funds opened new RGNX positions and 20 closed out — a net gain of 12 holders — while 47 added to existing stakes and 61 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $57.4M. The largest seller was Balyasny Asset Management, cutting an estimated $10.4M.

  • 171 institutional investors held Regenxbio (RGNX) as of Q4 2023, up from 159 in Q3 2023.
  • Funds reported $717M of Regenxbio stock for Q4 2023, up 18% quarter-over-quarter.
  • 32 funds opened new Regenxbio positions in Q4 2023 and 20 closed out, a net change of +12 holders.
  • The largest Regenxbio buyer in Q4 2023 was Morgan Stanley, an estimated $57.4M added.
  • The largest Regenxbio seller in Q4 2023 was Balyasny Asset Management, an estimated $10.4M sold.

Based on aggregated 13F filings for Q4 2023.